TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding TScan Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 29 | 25 | −4 |
| Shares | 9.86M | 9.41M | −454.3K (−4.6%) |
| Value | $44.4M | $26.3M | −$18.0M (−40.6%) |
New holders (4)
Institutions that held TScan Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tang Capital Management LLC | 200,000 | $560.0K | 0.11% |
| Barclays PLC | 158,944 | $445.0K | 0.00% |
| Renaissance Technologies LLC | 13,300 | $37.0K | 0.00% |
| JPMorgan Chase & Co | 361 | $1.00K | 0.00% |
Sold out (8)
Institutions that held TScan Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Nan Fung Group Holdings Ltd | 48,600 | $219.0K |
| Caas Capital Management LP | 25,633 | $115.0K |
| HRT Financial LP | 20,829 | $93.0K |
| LPL Financial LLC | 13,000 | $59.0K |
| Millennium Management LLC | 12,276 | $55.0K |
| Jane Street Group, LLC | 11,307 | $51.0K |
| UBS Group AG | 811 | $4.00K |
| Bank of America Corp | 189 | $1.00K |